Vaccinex, Inc. (VCNX)

6.00 -0.50 (-7.69%) At close: 04:00PM EDT

Vaccinex, Inc.

1895 Mount Hope Avenue
Rochester, NY 14620
United States
585 271 2700
https://www.vaccinex.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Maurice Zauderer Ph.D.	Co-Founder, CEO, President & Director	411.7k	N/A	1947
Dr. Elizabeth E. Evans Ph.D.	COO and Senior VP of Discovery & Translational Medicine	291.57k	N/A	1973
Dr. Ernest S. Smith Ph.D.	Senior VP of Research & Chief Scientific Officer	297.25k	N/A	1972
Ms. Jill Sanchez CPA	Chief Financial Officer	N/A	N/A	1972
Dr. John E. Leonard Ph.D.	Senior Vice President of Development	N/A	N/A	1947

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Corporate governance

Vaccinex, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.